The top medtech stories of early 2017

Abbott Laboratories’s bioresorbable Absorb stent.

FDA warning about Abbott’s Absorb stent

Abbott Labs’s Absorb bioresorbable stent was one of the most promising medical devices that FDA approved last year. Now, there is a cloud over the stent’s potential after FDA this month issued a warning to physicians.

FDA issued the warning after new study data that showed that Absorb had a higher risk of serious adverse events at 2 years compared with the company’s Xience drug-eluting stent. Nearly a fifth of the 2,008 patients in the study, however, had stents implanted in arteries that are now considered too small for the device. Exclude the patients with the too-small arteries, and there was no statistical significance between Absorb and Xience in the study.

Next>>

Engineering Better Devices at DeviceTalks Minnesota DeviceTalks Minnesota's engineering track is designed to provide attendees with with actionable lessons in a peer-to-peer format on topics such as: Human factors engineering Patient-centric device development R&D trends Manufacturing and scalability Navigating the product development process from start to finish "How We Built This" panels with top medical device groups Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code DT15 to save 15%! REGISTER NOW

Pages: 1 2 3 4 5 6